Clinical potential of the ERG oncoprotein in prostate cancer (Q37983732)

26 August 2017

title

Clinical potential of the ERG oncoprotein in prostate cancer (English)

1 reference

26 August 2017

1 reference

Philip Rosen

1

1 reference

26 August 2017

Isabell A Sesterhenn

2

1 reference

26 August 2017

Stephen A Brassell

3

1 reference

26 August 2017

David G McLeod

4

1 reference

26 August 2017

Shiv Srivastava

5

1 reference

26 August 2017

Albert Dobi

6

1 reference

26 August 2017

language of work or name

English

0 references

publication date

14 February 2012

1 reference

26 August 2017

published in

Nature Reviews Urology

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

131-137

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Recurrent gene fusions in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Common gene rearrangements in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ETS gene fusions in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Fusion in the ETS gene family and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Role of the TMPRSS2-ERG gene fusion in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

A causal role for ERG in neoplastic transformation of prostate epithelium.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ERG oncogene modulates prostaglandin signaling in prostate cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Integrative molecular concept modeling of prostate cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ETS gene fusions in prostate cancer: from discovery to daily clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

The erg gene: a human gene related to the ets oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Antibody-based detection of ERG rearrangement-positive prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Delineation of TMPRSS2-ERG splice variants in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

The role of the ETS factor erg in zebrafish vasculogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ERG gene rearrangement status in prostate cancer detected by immunohistochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Single focus prostate cancer: pathological features and ERG fusion status.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

ERG gene rearrangements are common in prostatic small cell carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Complex patterns of ETS gene alteration arise during cancer development in the human prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

31 March 2020

MYC and Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Gene fusions find an ERG-way to tumor inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2012.10

Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript

31 March 2020

1 reference

12 December 2020

Oncogenic activation of ERG: A predominant mechanism in prostate cancer

1 reference

12 December 2020

Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression

1 reference

12 December 2020

Xl erg: expression pattern and overexpression during development plead for a role in endothelial cell differentiation

1 reference

12 December 2020

Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2012.10

1 reference

26 August 2017

1 reference